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Strikingly Different Clinicopathological Phenotypes
Determined by Progranulin-Mutation Dosage
Katherine R. Smith,1,2 John Damiano,3 Silvana Franceschetti,4 Stirling Carpenter,5 Laura Canafoglia,4
Michela Morbin,6 Giacomina Rossi,6 Davide Pareyson,7 Sara E. Mole,8 John F. Staropoli,9
Katherine B. Sims,9 Jada Lewis,10 Wen-Lang Lin,11 Dennis W. Dickson,11 Hans-Henrik Dahl,3
Melanie Bahlo,1,12,* and Samuel F. Berkovic3,*
We performed hypothesis-free linkage analysis and exome sequencing in a family with two siblings who had neuronal ceroid lipofusci-
nosis (NCL). Two linkage peaks with maximum LOD scores of 3.07 and 2.97 were found on chromosomes 7 and 17, respectively. Unex-
pectedly, we found these siblings to be homozygous for a c.813_816del (p.Thr272Serfs*10) mutation in the progranulin gene (GRN,
granulin precursor) in the latter peak. Heterozygous mutations in GRN are a major cause of frontotemporal lobar degeneration with
TDP-43 inclusions (FTLD-TDP), the second most common early-onset dementia. Reexamination of progranulin-deficient mice revealed
rectilinear profiles typical of NCL. The age-at-onset and neuropathology of FTLD-TDP and NCL are markedly different. Our findings
reveal an unanticipated link between a rare and a common neurological disorder and illustrate pleiotropic effects of a mutation in
the heterozygous or homozygous states.The neuronal ceroid lipofuscinoses (NCLs) are neurode-
generative diseases characterized by storage of abnormal
lipopigment in lysosomes. The more common child-
hood-onset forms, which are usually associated with visual
failure, are due to recessive mutations in a group of genes
believed to be involved in lysosomal processing.1 Adult-
onset cases are rarer and can present with or without reti-
nopathy; the genetic causes are now being unraveled.2,3
We employed genetic linkage analysis and massively
parallel sequencing to identify the genetic cause of NCL
with retinopathy in a family with apparent recessive inher-
itance for whom screening of likely known genes (PPT1
[MIM 600722], CLN3 [MIM 607042], and CLN6 [MIM
606725]) was unrewarding. Two siblings with apparently
unrelated, healthy parents were affected (Figure 1A). The
28-year-old proband presented with rapidly progressive
visual failure at 22 years, followed by major convulsions
at 25 years, and myoclonic seizures at 26 years. Clinical
examination showedmild cerebellar ataxia, early cognitive
deterioration, and retinal dystrophy (Figure 1B). Electroen-
cephalogram (EEG) results showed generalized polyspike
wave discharges, electroretinogram results showed severe
attenuation of both rod and cone responses, and MRI
results showed cerebellar atrophy. Electron microscopic
examination of a skin biopsy demonstrated numerous
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proband’s 26-year-old sister began having recurrent
convulsions at 23 years, sometimes preceded by visual
distortions. Her vision was initially normal but deterio-
rated when she was 25 years old. Examination revealed
cerebellar ataxia and retinal dystrophy. EEG results showed
polyspike wave discharges with a posterior emphasis, and
MRI results revealed cerebellar atrophy.
Clinical studies were approved by the Human Research
Ethics Committee of Austin Health, Melbourne, Australia,
and written informed consent was obtained from partici-
pating family members. DNA isolated from blood samples
of the two affected siblings and their parents was geno-
typed through the use of Illumina Infinium Human-
Hap610W-Quad BeadChip genotyping arrays at the
Australian Genome Research Facility (Melbourne). We
analyzed genotypes for a subset of 11,572 SNP markers
that have high heterozygosity and are in approximate
linkage equilibrium (one SNP was chosen per 0.3 cM).
Marker selection was performed by the Perl script
linkdatagen.pl.4
Although the parents were not known to be related,
they came from nearby small villages in Lombardy, Italy.
To determine whether consanguinity was present, we
estimated the inbreeding coefficients (F) of the affected
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Figure 1. Family Pedigree and Clinical Features of NCL in
Proband
(A) Pedigree of family (arrow indicates proband) indicating muta-
tion status for GRN (c.813_816del). Plasma progranulin values are
shown in red (ng/ml; median normal value is 126 ng/ml).
(B) Retinal photograph of proband showing optic atrophy, arteri-
olar attenuation, and irregular retinal pigmentation.
(C) Electron micrograph of skin biopsy from the proband. Typical
fingerprint profiles within a membrane-bound structure in an ec-
crine pale cell are shown. The bar indicates 100 nm.son and F ¼ 0.006 for the affected daughter. This suggests
that the parents are distantly related (approximately
second cousins once removed; expected F ¼ 0.0078).
To ascertain the chromosomal locus, we performed an
initial multipoint parametric linkage analysis that assumed
no relationship between the two parents using MERLIN.6
We specified a fully penetrant recessive genetic model,
a disease allele frequency of 0.0001, and allele frequencies
from the Centre d’Etude du Polymorphisme Humain
(CEPH; Utah residents with ancestry from northern and
western Europe) HapMap population. FEstim was then
used to adjust the LOD scores produced by MERLIN to
account for the estimated inbreeding.7
This analysis revealed two linkage peaks located on chro-
mosomes 7 and 17 (Figure 2). These peaks do not overlap
any of the following genes previously implicated in NCL:
PPT1, TPP1, CLN3, CLN5, CLN6, MFSD8, CLN8, CTSD, or
DNAJC5. The linkage peak on chromosome 7 achieved
a maximum adjusted LOD score of 3.07 and was located
between rs1981701 and rs318572 (50.54 to 54.14 cM via
deCODE), spanning 3.19 Mb and encompassing 25 genes.
The linkage peak on chromosome 17 achieved amaximum
adjusted LOD score of 2.97 and was located betweenThe Americrs2019231 and rs3809854 (70.07 to 73.75 cM); it spanned
5.42 Mb and encompassed 186 genes.
To efficiently identify a potential causative mutation,
we sequenced the exomes of the two parents and their
affected son. Exome capture and sequencing was per-
formed by Axeq Technologies (Rockville, MD, USA).
DNA samples were enriched for approximately 62 Mb of
the genome identified as being ‘‘exomic’’ with the use
of Illumina TruSeq capture and sequenced using an Illu-
mina HiSeq 2000 machine, generating 110 bp paired-
end reads.
Reads were aligned to the hg19 reference genome with
the use of Novoalign, with quality score calibration per-
formed. Multimapping reads were removed; potential
PCR duplicates were removed with Picard. Variants were
called with the mpileup and bcftools view utilities from
the SAMtools package8,9 and filtered with the vcfutils.pl
script from the same package. Variants were annotated
with ANNOVAR.10 We used HumVar-trained PolyPhen-2
(v2.1.0r367) to predict the biological impact of nonsynon-
ymous variants.11
Table S1, available online, summarizes the number of
reads mapped to each exome, and Table S2 summarizes
the distribution of coverage for targeted bases.
We detected 325,946 variants from the reference
sequence in at least one member of the trio. No rare
(not reported or with frequencies of less than 1% in the
1000 Genomes May 2011 release12) exonic or splice-site
variants were detected in PPT1, TPP1, CLN3, CLN5,
CLN6, MFSD8, CLN8, CTSD, or DNAJC5. A total of 1,688
variants (0.52%) were located within the two linkage
regions, of which 352 were rare and 20 were predicted to
affect exonic regions or splice sites. All of these 20 variants
were located within the linkage peak on chromosome 17.
We discarded three variants that resulted in synonymous
changes not predicted to affect splicing. Of the remaining
17 variants, three had inferred genotypes following the
pattern expected under the consanguineous recessive
disease model (i.e., the affected son was homozygous
and unaffected parents were heterozygous; missing geno-
types were permitted).
The three candidate disease-causing variants are
described in Table S3. All three variants were present in
dbSNP 132. Two variants (in DBF4B [MIM 611661] and
ADAM11 [MIM 155120]) were present in the 1000
Genomes data set, both with an alternate allele frequency
of 0.006. The third variant was not present in the 1000
Genomes data set, but was a known pathogenic mutation:
a 4 bp deletion in GRN (MIM 138945; NM_002087.2),
which encodes progranulin (also known as the granulin
precursor). The c.813_816del mutation (rs63749877)
results in a frameshift and premature termination of trans-
lation 10 residues downstream (p.Thr272Serfs*10). Sanger
sequencing confirmed that the variant was genuine and
segregated as expected in the family, with the mother
and father heterozygous for the variant and both affected
children homozygous.an Journal of Human Genetics 90, 1102–1107, June 8, 2012 1103
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Figure 2. Results of Linkage Analysis
Autosomal genome-wide LOD scores, adjusted for inbreeding, for the family under a fully penetrant recessive genetic model.Heterozygous c.813_816del GRN mutations are known
to cause frontotemporal lobar degeneration13–16 (FTLD-
TDP; MIM 607485). This presents in later life, so we reeval-
uated the family for features of frontal lobe dementia.
There was a history of late dementia (approximately
seventh decade) in the maternal grandfather, paternal
grandmother, and great uncle; as all three individuals are
deceased, pathological diagnoses could not be made, and
DNA could not be obtained. A number of older relatives
had died before 55 years of age, so a more obvious pattern
of autosomal-dominant dementia may have been masked.
The parents, both heterozygous for the mutation, were in
their fifties and healthy. DNA from all available family
members was screened. The results (Figure 1) indicate
that the mother must have inherited the c.813_816del
mutation from her father, who had dementia, and that
an additional family member in the parents’ generation
is a c.813_816del heterozygote. Plasma progranulin was
measured in available family members with a commercial
kit (Human Progranulin ELISA Kit, AdipoGen, Seoul, South
Korea).17 Plasma progranulin correlated with the geno-
types; values were 125–143 ng/ml in three individuals
with no copies of the deletion (median normal value:
126 ng/ml17), 33–48 ng/ml in the three heterozygous
subjects, which is below the cutoff value (62 ng/ml) for
predicting heterozygous null mutations,17 and undetect-
able (<0.6 ng/ml) in the two homozygous affected siblings
(Figure 1A).
Subsequently, we sequenced 20 unrelated cases of
proven or suspected adult NCL wherein known NCL genes
had been excluded. All 13 exons, exon-intron boundaries,
and untranslated regions of GRN were PCR-amplified,
sequenced with the BigDye Terminator v3.1 Cycle
Sequencing protocol, and run on an ABI 3730XL DNA1104 The American Journal of Human Genetics 90, 1102–1107, JuneAnalyzer (Life Technologies, Carlsbad, CA, USA). We did
not find homozygous or compound-heterozygous muta-
tions in any of these individuals, although one was found
to be heterozygous for the most common GRN mutation,
c.1477C>T (p.Arg493*; rs63751294).18 This patient pre-
sented with limb dystonia, spasticity, gait disturbance,
apraxia, and dementia at the age of 46. Death occurred
around the age of 48–49. We excluded the possibility
that this individual had a partial deletion of the second
GRN allele by performing a multiplex ligation-dependent
probe amplification assay. We were unable to reevaluate
the original diagnosis of NCL as the original electron
micrographs and tissue samples were unavailable. This
diagnosis was made on the basis of lymphocyte inclusions,
which may be unreliable in adult NCL; we suspect that the
individual may have had FTLD-TDP misdiagnosed as adult
NCL. We also sequenced the same regions of GRN for 188
anonymous blood-bank controls without detecting any
known mutations or novel variants.
Ahmed et al. previously generated mice deficient in the
orthologous Grn (Grn/) and reported accumulation of
abnormal intraneuronal ubiquitin-positive autofluores-
cent lipofuscin detected by light microscopy.19 This
finding has since been replicated with the use of indepen-
dently generated Grn-deficient mice.20 Electron micro-
scopic examination of fixed brain tissue from the Ahmed
et al. mice revealed abundant rectilinear profiles diagnostic
of NCL (Figure 3). Animal studies were performed in accor-
dance with the Mayo Clinic Institutional Animal Care and
Use Committee.
We report that homozygous c.813_816del mutations in
GRN cause adult-onset NCL and suggest that this locus
be designated CLN11. This result is remarkable, given
that mutations in this gene are an important cause of8, 2012
Figure 3. NCL Pathology in Progranulin-Deficient Mice
Electron micrograph showing a high-power view of one of the
storage granules in a neuron from the habenula of aGrn/mouse.
The pattern corresponds to the rectilinear complex, which, along
with fingerprint profiles, is characteristic of most types of NCL.
The arrow points to a pentalaminar profile. The bar indicates
100 nm.FTLD-TDP in the heterozygous state and that the two clin-
ically distinct neurological disorders have very different
pathologies.
Clinically, mutations in specific genes usually determine
important phenotypes in either the heterozygous or
homozygous state, but not both. In classical recessive
disorders, heterozygous individuals are usually healthy,
asymptomatic carriers, although there may be a clinically
trivial or biochemical phenotype or sometimes even
a survival advantage, such as for sickle cell trait (MIM
603903).21 In classical dominant disorders, the population
allele frequency is low, so homozygous individuals are
exceptional, except in inbred communities.22 When
observed, such rare homozygous cases may differ little
from heterozygous family members (e.g., in Huntington
disease [MIM 143100] and epidermolysis bullosa simplex
[MIM 131900]) or have a more severe form of the same
phenotype, suggesting an additive effect on the gene
product dysfunction (e.g., in Marfan syndrome [MIM
154700], achondroplasia [MIM 100800], and Charcot-
Marie-Tooth disease [MIM 118200]).22
One example of different diseases with homozygous
versus heterozygous mutations involves the gene that
encodes acid beta-glucosidase (GBA [MIM 606463]).
Homozygous GBA mutations have been long known to
cause the various forms of Gaucher disease (MIMs
608013, 230800, 230900, 231000, and 231005), where
there is storage of glucocerebroside. More recently, various
heterozygous GBAmutations have been shown to increase
the risk of late-onset Parkinson disease (MIM 168600), not
as aMendelian trait but rather as a susceptibility factor.23,24
Although the present result was unexpected and we did
not identify additional cases, the finding of similar andThe Americdiagnostic electron-microscopic features of NCL in the
human material and in the progranulin-deficient mouse
supports our conclusion of strikingly different phenotypes
for this GRN mutation depending on whether it is homo-
zygous or heterozygous. The sibling pair had early-adult
onset of severe retinal disease with seizures, ataxia, and
cognitive change. Although brain biopsies were not avail-
able from the siblings, themouse brain pathologymirrored
the known human pathology of NCL in its storage of
abnormal autofluorescent lipopigment with characteristic
ultrastructural features in neurons.25,26 This contrasts
with FTLD-TDP due to heterozygous GRN mutation;
the disorder presents in later life with behavioral and
cognitive impairment, but seizures are unusual, and ataxia
and retinal involvement are absent. The pathology does
not reveal lipopigment storage material but rather
neurons with TDP-43-immunoreactive neuronal and glial
inclusions.27,28
To the best of our knowledge, homozygous mutations
have not previously been reported in GRN. Indeed, Bruni
et al.29 found no homozygotes in a highly consanguineous
Calabrian family in which 19 individuals were found to be
heterozygous for a c.1144dup (p.Thr382Asnfs*32) muta-
tion in GRN. The authors speculated that the loss of both
GRN alleles might cause embryonic lethality,29 but our
data showing homozygotes with undetectable progranulin
levels and the viability of the Grn/mouse show that pro-
granulin deficiency is compatible with life.
Progranulin has multiple physiological roles, and it
influences inflammation, early embryogenesis, tumorigen-
esis, and adult tissue repair.30 How haploinsufficiency
causes FTLD-TDP remains uncertain. In Caenorhabditis
elegans, progranulin deficiency causes more rapid clearance
of apoptotic cells and inadvertently results in the clearance
of neurons that would otherwise recover from initiation of
apoptosis.31 This observation, however, does not explain
how progranulin deficiency would result in NCL. Given
the link between NCL and proteins that affect lysosomal
processing, the association between GRN mutation and
NCL suggests that progranulin has a lysosomal function.
There is good evidence that progranulin is neurotrophic
or neuroprotective,30 potentially through the modulation
of survival signaling. Disruption of cell signaling processes
could conceivably result in rapid ‘‘aging’’ of unprotected
progranulin-deficient cells with respect to lipofuscinosis.
Indeed, homozygous GRN deficiency in mice results in mi-
croglial activation, increased ubiquitination, and excess
lipopigment deposition.19
The history of dementia in this family was not regarded
as remarkable when first assessed. Early death in many
older family members masked the likely autosomal-domi-
nant pattern on both sides of the family (Figure 1A). It
has been estimated that 50% of c.813_816del heterozy-
gotes show symptoms by the age of 63 and that 97.3%
are symptomatic by the age of 73.14 Thus, the discovery
of homozygous mutation in children presents an unex-
pected ethical dilemma in terms of new knowledgean Journal of Human Genetics 90, 1102–1107, June 8, 2012 1105
regarding the likelihood of late-life dementia in the parents
and other healthy heterozygotes.
With the recent widespread implementation of
massively parallel sequencing to uncover causes of hith-
erto obscure early-onset recessive phenotypes,32 even in
single families as here, further examples of pleiotropic
effects of homozygous and heterozygous mutations may
emerge. This will create opportunities for better patho-
physiological understanding, but may also result in
unexpected ethical quandaries upon the emergence of
age-dependent heterozygous phenotypes.Supplemental Data
Supplemental Data include three tables and can be foundwith this
article online at http://www.cell.com/AJHG/.Acknowledgments
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